Top 10 Medicare Specialty Therapy Drugs

Ranked by 2014 PMPY Spend

Rank Drug Name Therapy Class PMPY Spend % of Total Specialty Spend Utilization Trend Unit Cost Trend Total Trend
1 Sovaldi® (sofosbuvir) Hepatitis C $66.22 9.1% 15,624.4% 476.7% 16,101.1%
2 Revlimid® (lenalidomide) Oncology $47.78 6.6% 14.1% 6.3% 20.3%
3 Copaxone® (glatiramer) Multiple Sclerosis $36.91 5.1% -2.2% 10.2% 8.0%
4 Enbrel® (etanercept) Inflammatory Conditions $33.46 4.6% 3.4% 17.0% 20.4%
5 Humira® (adalimumab) Inflammatory Conditions $33.17 4.6% 6.4% 17.6% 24.0%
6 Gleevec® (imatinib) Oncology $29.31 4.0% 6.0% 20.4% 26.4%
7 Zytiga® (abiraterone) Oncology $21.05 2.9% 39.9% 14.2% 54.1%
8 Olysio® (simeprevir) Hepatitis C $18.60 2.6% 25,964.2% 64.5% 26,028.7%
9 Harvoni® (ledipasvir/sofosbuvir) Hepatitis C $18.01 2.5% N/A N/A N/A
10 Avonex® (interferon beta 1-a) Multiple Sclerosis $17.66 2.4% -4.4% 11.6% 7.2%